Zemidapa Dosage/Direction for Use

Posology: Adults: The recommended dose is one tablet once daily.
Special populations: Renal impairment: The efficacy and safety of Zemidapa is dependent on renal function, and renal function should be evaluated prior to initiation of Zemidapa and periodically thereafter.
For patients with eGFR ≥45 mL/min/1.73 m², no dose adjustment is required.
For patients with eGFR <45 mL/min/1.73 m², Zemidapa is not recommended.
Hepatic impairment: No dose adjustment is required for patient with mild or moderate hepatic impairment. The safety and efficacy of Zemidapa in patients with severe hepatic impairment have not yet been established.
Cardiac impairment: There is limited experience in patients with New York Heart Association (NYHA) Class I, II cardiac status in the case of gemigliptin. Therefore, Zemidapa should be used with caution in this population. Due to limited clinical experience in patients with NYHA Class III, IV cardiac status in the case of gemigliptin, the use of Zemidapa is not recommended in this population.
Elderly: Caution should be used in elderly patients because physiological functions including liver and kidney are usually decreased in this population.
Pediatric population: Safety and effectiveness in children and adolescents below 18 years of age have not been established. No data are available.
Method of administration: Zemidapa can be taken orally once daily with or without food.